Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free GUD Stock Alerts

Knight Therapeutics (GUD) Competitors

Knight Therapeutics logo
C$10.58 -0.01 (-0.09%)
As of 02:02 PM Eastern
Compare

GUD vs. BHC, CRON, MJN, CARA, and DHT.UN

Should you buy Knight Therapeutics stock or one of its competitors? Knight Therapeutics's main competitors and comparable companies include Bausch Health Companies (BHC), Cronos Group (CRON), Cronos Group (MJN), Cara Operations (CARA), and DRI Healthcare Trust (DHT.UN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Knight Therapeutics compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Knight Therapeutics (TSE:GUD) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Knight Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health CompaniesC$10.85B0.28-C$125.65M-C$2.94N/A
Knight TherapeuticsC$547.31M1.90-C$30.73MC$0.1570.53

Bausch Health Companies has a beta of 0.707626, meaning that its share price is 29% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.290935, meaning that its share price is 129% less volatile than the broader market.

Knight Therapeutics has a consensus target price of C$9.50, suggesting a potential downside of 10.21%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than Bausch Health Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Companies
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Knight Therapeutics has a net margin of 2.72% compared to Bausch Health Companies' net margin of -12.02%. Bausch Health Companies' return on equity of 87.57% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Companies-12.02% 87.57% 4.16%
Knight Therapeutics 2.72%1.91%0.51%

9.7% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 22.7% of Knight Therapeutics shares are owned by institutional investors. 11.3% of Bausch Health Companies shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Bausch Health Companies and Bausch Health Companies both had 6 articles in the media. Bausch Health Companies' average media sentiment score of 0.89 beat Knight Therapeutics' score of 0.45 indicating that Bausch Health Companies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bausch Health Companies
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Knight Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Knight Therapeutics beats Bausch Health Companies on 10 of the 15 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Cronos Group (TSE:CRON) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Knight Therapeutics had 3 more articles in the media than Cronos Group. MarketBeat recorded 6 mentions for Knight Therapeutics and 3 mentions for Cronos Group. Knight Therapeutics' average media sentiment score of 0.45 beat Cronos Group's score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cronos Group
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Knight Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cronos Group has a beta of 1.29991, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.290935, suggesting that its stock price is 129% less volatile than the broader market.

4.3% of Cronos Group shares are held by institutional investors. Comparatively, 22.7% of Knight Therapeutics shares are held by institutional investors. 46.4% of Cronos Group shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Knight Therapeutics has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupC$179.09M9.48-C$32.78MC$0.1924.26
Knight TherapeuticsC$547.31M1.90-C$30.73MC$0.1570.53

Cronos Group presently has a consensus target price of C$4.92, suggesting a potential upside of 6.65%. Knight Therapeutics has a consensus target price of C$9.50, suggesting a potential downside of 10.21%. Given Cronos Group's higher possible upside, analysts clearly believe Cronos Group is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cronos Group has a net margin of 38.95% compared to Knight Therapeutics' net margin of 2.72%. Cronos Group's return on equity of 6.46% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group38.95% 6.46% -3.73%
Knight Therapeutics 2.72%1.91%0.51%

Summary

Cronos Group beats Knight Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Knight Therapeutics (TSE:GUD) and Cronos Group (CVE:MJN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Cronos Group has lower revenue, but higher earnings than Knight Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$547.31M1.90-C$30.73MC$0.1570.53
Cronos GroupN/AN/AN/AN/AN/A

Knight Therapeutics presently has a consensus price target of C$9.50, indicating a potential downside of 10.21%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Knight Therapeutics had 6 more articles in the media than Cronos Group. MarketBeat recorded 6 mentions for Knight Therapeutics and 0 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.11 beat Knight Therapeutics' score of 0.45 indicating that Cronos Group is being referred to more favorably in the news media.

Company Overall Sentiment
Knight Therapeutics Neutral
Cronos Group Positive

22.7% of Knight Therapeutics shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Knight Therapeutics has a net margin of 2.72% compared to Cronos Group's net margin of 0.00%. Knight Therapeutics' return on equity of 1.91% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics2.72% 1.91% 0.51%
Cronos Group N/A N/A N/A

Summary

Knight Therapeutics beats Cronos Group on 10 of the 11 factors compared between the two stocks.

How does Knight Therapeutics compare to Cara Operations?

Cara Operations (TSE:CARA) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Knight Therapeutics has a net margin of 2.72% compared to Cara Operations' net margin of 0.00%. Knight Therapeutics' return on equity of 1.91% beat Cara Operations' return on equity.

Company Net Margins Return on Equity Return on Assets
Cara OperationsN/A N/A N/A
Knight Therapeutics 2.72%1.91%0.51%

Cara Operations has higher earnings, but lower revenue than Knight Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara OperationsN/AN/AN/AN/AN/A
Knight TherapeuticsC$547.31M1.90-C$30.73MC$0.1570.53

Knight Therapeutics has a consensus price target of C$9.50, suggesting a potential downside of 10.21%. Given Cara Operations' higher probable upside, research analysts plainly believe Cara Operations is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cara Operations
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Knight Therapeutics had 6 more articles in the media than Cara Operations. MarketBeat recorded 6 mentions for Knight Therapeutics and 0 mentions for Cara Operations. Knight Therapeutics' average media sentiment score of 0.45 beat Cara Operations' score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cara Operations Neutral
Knight Therapeutics Neutral

22.7% of Knight Therapeutics shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Knight Therapeutics beats Cara Operations on 10 of the 11 factors compared between the two stocks.

How does Knight Therapeutics compare to DRI Healthcare Trust?

Knight Therapeutics (TSE:GUD) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Knight Therapeutics has a beta of -0.290935, indicating that its share price is 129% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.365327, indicating that its share price is 63% less volatile than the broader market.

Knight Therapeutics presently has a consensus price target of C$9.50, suggesting a potential downside of 10.21%. DRI Healthcare Trust has a consensus price target of C$25.60, suggesting a potential upside of 41.20%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, analysts plainly believe DRI Healthcare Trust is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

DRI Healthcare Trust has lower revenue, but higher earnings than Knight Therapeutics. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$547.31M1.90-C$30.73MC$0.1570.53
DRI Healthcare TrustC$172.34M5.79C$9.73M-C$0.80N/A

22.7% of Knight Therapeutics shares are owned by institutional investors. Comparatively, 0.8% of DRI Healthcare Trust shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by company insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

DRI Healthcare Trust has a net margin of 5.02% compared to Knight Therapeutics' net margin of 2.72%. DRI Healthcare Trust's return on equity of 2.06% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics2.72% 1.91% 0.51%
DRI Healthcare Trust 5.02%2.06%4.22%

In the previous week, Knight Therapeutics had 5 more articles in the media than DRI Healthcare Trust. MarketBeat recorded 6 mentions for Knight Therapeutics and 1 mentions for DRI Healthcare Trust. DRI Healthcare Trust's average media sentiment score of 0.58 beat Knight Therapeutics' score of 0.45 indicating that DRI Healthcare Trust is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Knight Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DRI Healthcare Trust
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

DRI Healthcare Trust beats Knight Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Knight Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GUD vs. The Competition

Export
MetricKnight TherapeuticsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$1.04BC$12.26BC$7.13BC$12.43B
Dividend YieldN/A2.62%2.52%6.31%
P/E Ratio70.53797.15273.6439.38
Price / Sales1.90938.56656.979.10
Price / Cash3.8591.2879.7582.29
Price / Book1.3010.3110.544.60
Net Income-C$30.73MC$2.84BC$3.50BC$299.09M
7 Day Performance4.75%-1.87%-2.04%-1.35%
1 Month Performance9.75%-5.29%-5.21%-2.03%
1 Year Performance78.41%-2.63%10.28%16.16%

Knight Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GUD
Knight Therapeutics
0.6627 of 5 stars		C$10.58
-0.1%		C$9.50
-10.2%		+80.1%C$1.04BC$547.31M70.53830
BHC
Bausch Health Companies
0.8373 of 5 stars		C$8.02
-0.2%		N/A-7.5%C$3.00BC$10.85BN/A20,300
CRON
Cronos Group
1.4792 of 5 stars		C$4.73
-1.7%		C$4.92
+3.9%		+22.1%C$1.74BC$179.09M24.89610
MJN
Cronos Group
N/AC$12.15
-1.9%		N/A+0.0%C$1.73BN/AN/A7,600
CARA
Cara Operations
N/AN/AN/AN/AC$1.62BN/AN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:GUD) was last updated on 10/1/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel